Chemotherapy of stage IIIB and IV non-small-cell lung cancer
Chemotherapy of stage IIIB and IV non-small-cell lung cancer
复制标题
DOI：
10.1093/annonc/6.suppl_3.s41
复制
发表时间：
1995-01-01
影响因子：
50.5
通讯作者：
LeChevalier, T
中科院分区：
文献类型：
--
作者：
Cojean, I;LeChevalier, T
目前，肺癌是男性死亡的主要原因，每年诊断出50多万新病例。这些肿瘤中的80%是非小细胞癌，其中70%在出现时不可切除或转移，导致生存率极低。越来越多的药物显示出对非小细胞肺癌的显着活性和现代顺铂为基础的方案的广泛使用提供了一些进展的希望，并表明化疗可能在治疗这种疾病中发挥作用。最近的一项荟萃分析证实，在转移性疾病和局部晚期疾病中，联合化疗治疗的患者的生存获益虽然不大，但意义重大。
Currently, lung cancer is a leading cause of death in men with more than half million new cases diagnosed every year. Eighty percent of these tumors are non-small-cell carcinoma and 70% of these are unresectable or metastatic at the time of presentation, resulting in dramatically poor survival rates. The increasing number of drugs showing a significant activity against non-small-cell lung cancer and the widespread use of modern cisplatin based regimens offer some hope of progress and suggest that chemotherapy may have a role in treating this disease. A recent meta-analysis has confirmed the modest but significant survival benefit for patients treated with combined chemotherapy both in case of metastatic disease and in addition to radiotherapy, in locally advanced disease.